<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751751</url>
  </required_header>
  <id_info>
    <org_study_id>SE-866/36</org_study_id>
    <nct_id>NCT00751751</nct_id>
  </id_info>
  <brief_title>Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly</brief_title>
  <official_title>Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of individually optimized doses of olmesartan medoxomil compared to
      losartan in elderly and very elderly patients with essential hypertension. The study
      hypothesis is non-inferiority of olmesartan medoxomil compared to losartan in lowering mean
      sitting diastolic blood pressure after 12 weeks of treatment compared to baseline. The study
      duration is up to 60 weeks, including a 52-week treatment period. After 12 weeks of treatment
      hydrochlorothiazide may be added to control blood pressure. Efficacy and safety measurements
      are carried out at up to 18 visits during the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean sitting diastolic blood pressure assessed by conventional BP measurements</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean sitting diastolic BP assessed by conventional BP measurements</measure>
    <time_frame>after 1, 2, 4, 8, 16, 20, 28, 36, 44, and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean standing diastolic BP, mean sitting systolic BP and mean standing systolic BP</measure>
    <time_frame>after 1, 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">441</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + hydrochlorothiazide, if necessary</intervention_name>
    <description>oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan + hydrochlorothiazide, if necessary</intervention_name>
    <description>oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65 years or older

          -  Mean sitting diastolic BP = 100-114 mmHg and mean sitting systolic BP &gt;=150 mm HG

        Exclusion Criteria:

          -  Secondary hypertension

          -  Malignant hypertension

          -  Severe heart failure (NYHA III-IV)

          -  History or evidence of renal disease

          -  Recent history of myocardial infarction

          -  Hypersensitivity to study drugs

          -  History of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter U Witte, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMFORM GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Petra Laeis, Ph.D.</name_title>
    <organization>Daiichi Sankyo Europe, GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

